American College of Obstetricians and Gynecologists // 
Physicians, Women // Health Care // 
Practice Experience // 
replaces - RoleLinkType // Numbers // Numbers // Practice Experience // 
Screening for cancer // Thoracic mammary region // 
Diagnosis // Most // Woman // Primary malignant neoplasm // Cause of death.secondary:Find:Pt:^Patient:Nom // United States // From // Leading // Woman // American // Singular // Second Primary Cancers // 1+ Score // Malignant neoplasm of lung // 
Mortality Vital Statistics // Malignant neoplasm of breast // Aspects of disease screening // Reduced // 
Practice Experience // Purpose // Act Class - review // To // Guideline [Publication Type] // Screening for malignant neoplasm of breast // Used by // Evidence of // Supportive assistance // To // New // Recommendation // Modality // Aspects of disease screening // 
Aspects of disease screening // Surrounding (qualifier value) // 
Background // 
incidence of cases // 
account - ActClass // Malignant neoplasm of breast // Case unit dose // New // 2+ Score // Woman // 
Risk // Female Breast Carcinoma // 2+ Score // Table - furniture // 3+ Score // 
2010s // New // Approximate // Invasive // Case unit dose // Diagnosis // Malignant neoplasm of breast // Attribution // Cessation of life // Malignant neoplasm of breast // 
Add - instruction imperative // Case unit dose // New // Malignant neoplasm of breast // In situ // 2010s // Reporting // 3+ Score // 
GPR162 gene // Decrease // per year // incidence of cases // Within // Body position // Malignant neoplasm of breast // Decreased // Reflecting // Hormone replacement therapy // Use of // Use of // Decreased // 3/5 // Screening mammography // 
Relationships // Malignant neoplasm of breast // Decreasing // Mortality Vital Statistics // Reflecting // 1990s // Screening for malignant neoplasm of breast // Bilateral // Therapeutic procedure // Better // 3+ Score // 
Component object // Aspects of disease screening // Malignant neoplasm of breast // Guideline [Publication Type] // Current (present time) // 
Including (qualifier) // Screening for malignant neoplasm of breast // Elements // Three // Entire breast // 1+ Score, WHO // Mammography // Diagnostic Imaging // Clinical Breast Examination // Integer +2 // Patients // &lt;3 (qualifier value) // Screening - procedure intent // subscriber - self // 
Table - furniture // 
Age // Probability // Specific qualifier value // Invasive Breast Carcinoma // 
Probability // Malignant neoplasm of breast // 

Current age // year // Following // 1+ Score, WHO // 


/40 // Arabic numeral 69 // 



Lifetime Risk // 
Primary malignant neoplasm // Free (available (qualifier)) // Beginning // At // Data Type Interval // Age // 
Case unit dose // Base - General Qualifier // Diagnosis // 
Money or percentage indicator - Percentage // Numbers // And // Equal // Negation // Round shape // 
Probability // Use of // Derivation // Computer software // National Cancer Institute // Version // 
Reprint // American Cancer Society // Authorization documentation // 
2010s // Malignant neoplasm of breast // 
American Cancer Society // Atlanta // 
Entire breast // Breast Self-Examination // Self awareness // 
Relative // Appropriate // Elements // Transcription Initiation // Age // Frequencies (time pattern) // Cessation // Aspects of disease screening // 
Committee // Gynecologist // Practice Experience // 
Committee // Practice Experience // Gynecologist // Practice Experience // Massive // Helping Behavior // 
Design // Information // Manufactured aid // To // Decision Making // Practitioner // Obstetrical // Appropriate // care activity // Gynecologic // 
Negation // Guidelines // Course // Exclusive // Interventional procedure // Therapeutic procedure // 
Within // Variant // Base - General Qualifier // Practice Experience // Patient need for (contextual qualifier) // Persons // Limitation // Resources // Health care facility // Unique // Practice Experience // Type - attribute // 
controversy // 
Table - furniture // Current (present time) // Outlines (document) // Guidelines // Screening procedure // Organization administrative structures // Major medical // 
College // American College of Obstetricians and Gynecologists // Inclusion // Continuous // strategy // Three // Screening procedure // Malignant neoplasm of breast // 
Screening mammography // 
Mammography // Indication of (contextual qualifier) // 
Neoplasm // Early // Detection // Small // Phase // More // Entire breast // Treated with // Probably // per year // In addition to // Localized // Continuance of life // &lt;3 (qualifier value) // N-(1-oxyl-2,2,5,5-tetramethyl-3-pyrrolidinyl)maleimide // 
year // Post // One // Follow-Up Studies // Present // Initially // Less Than // Neoplasm // Primary operation // Cure (remedy) // Axilla // Mastectomy // 
Confirmation // Scientific Study // In addition to // Result // Patients // &lt;90 // per year // Experience // Disease-Free Survival // Long // Neoplasm // Period (temporal qualifier) // Less Than // Measured // Mammography // Detection // Neoplasm // Probability // Neoplasm Metastasis // Negation // Treated with // Diagnosis // 
estimation &lt;subjective> // Mathematics // Ductal Breast Carcinoma // Usual // Population Mean // Constant (qualifier) // Temporal periods of day // Doubling // year // Presentation // size // Palpable // 
Mass of body structure // Screening mammography // Approximate // Measured // Phase // Preclinical // Palpable // 
concept // To // Referral placed // Time // Sojourn // Primary malignant neoplasm // Time Interval // Aspects of disease screening // Detection // Symptomatic // 
Sojourn // Individual // Time // Primary malignant neoplasm // Type - attribute // More // Varies // Aggressive course // biological // Short Value // Neoplasm // Time // Sojourn // 
Predictor // Greater // Time // Sojourn // Appearance // Malignant neoplasm of breast // Age // To // 
Population Mean // Estimated // Time // Sojourn // Female Breast Carcinoma // Preposition For // Age // Increase // Population Mean // year // year // Sojourn // 2/5 // year // Arabic numeral 69 // year // 3/5 // year // year // year // year // 
Population Mean // Time // Sojourn // Detected (finding) // Screening for malignant neoplasm of breast // Sojourn // Neoplasm // Period (temporal qualifier) // 
Individual // Type - attribute // Probably // Short Value // Primary malignant neoplasm // Time // Sojourn // Probably // More // Frequent // Benefits // Comparison // Aspects of disease screening // Neoplasm // Slow // Preclinical // Largest // Interval // 
Aspects of disease screening // Design // Egypt // Probability // To // Primary malignant neoplasm // Detected (finding) // Interval // Preclinical // Largest // treatment options // Better // Result // 
Mammography // Evaluation // 
Meta-Analysis (publications) // Recent // United States // Behavior // Advisory Committees // Preventive service healthcare // Eight // Review [Publication Type] // Within // Randomized Controlled Trials as Topic // Screening mammography // 
Study // Scientific Study // Limitation // Fair (qualifier) // Rating (action) // United States // Quality // Advisory Committees // Preventive service healthcare // Reduction - action // Act Class - review // Relationships // Malignant neoplasm of breast // Arabic numeral 69 // 
Table - furniture // 
Recommendation // Screening for malignant neoplasm of breast // 
Clinical // Mammography // Awareness // Breast self-examination technique education // 
Age-Years // American College of Obstetricians and Gynecologists // Old age // /40 // year // Annual // year // 1+ Score, WHO // /40 // Age // Annual // Old // High risk of // consider // Recommendation // Patients // 
Age-Years // American Cancer Society // Old age // /40 // year // Annual // year // 1+ Score, WHO // Age-Years // Optional // Recommendation // Old age // 
year // /40 // Annual // Old age // 
/40 // National Comprehensive Cancer Network // Old age // year // year // Annual // year // 1+ Score, WHO // Recommendation // Recommendation // 
/40 // Age-Years // Annual // Old age // 
/40 // National Cancer Institute // Old // year // year // Phase I/II Trial // Negation // Recommendation // Recommendation // 
United States // Advisory Committees // Preventive service healthcare // Insufficient (qualifier) // Age-Years // Negation // Evidence of // Recommendation // 
Aspects of disease screening // 
Mortality Vital Statistics // Consistent with // Meta Analysis (statistical procedure) // Previous // 18/22 // 
Relative Risk // Mortality Vital Statistics // Malignant neoplasm of breast // Aspects of disease screening // Woman // Age // Woman // Woman // year // year // Age // Woman // Arabic numeral 68 // Arabic numeral 69 // Age // year // 
Evidence of // Mortality Vital Statistics // Insufficient (qualifier) // Woman // Reduction - action // year // Age // Table - furniture // Old // 
Malignant neoplasm of breast // increasing incidence // Age // Woman // Young // More // Age-Years // Woman // Aspects of disease screening // To // One // PREVENT (product) // Relationships // Malignant neoplasm of breast // Comparison // Cessation of life // Woman // Old // Table - furniture // 
Numbers // Aspects of disease screening // Needs // Round shape // Over (spatial) // And // Aspects of disease screening // Follow-up status // year // PREVENT (product) // To // Malignant neoplasm of female breast // One // 1+ Score // year // Woman // Comparison // year // Age // 
Delta (difference) // This // Needs // Numbers // PREVENT (product) // Aspects of disease screening // Cessation of life // One // United States // Indication of (contextual qualifier) // Advisory Committees // Preventive service healthcare // Recommendation // Negation // Aspects of disease screening // Routine // year // Woman // Mortality Vital Statistics // Similarity // Arabic numeral 23 // Reduction - action // 
Research Design // Delta (difference) // Evaluation // Clinical Trials, Randomized // Randomized Controlled Trials as Topic // Aspects of disease screening // Providing (action) // Negation // Comparison // Meaning // Aspects of disease screening // Different // Term (temporal) // strategy // Cognitive function: initiation // Age // Frequencies (time pattern) // 
Lacking // Evidence of // Clear // Light Emitting Diode Device Component // Problem // Preventive service healthcare // United States // Surgical construction // Advisory Committees // Model // Aspects of disease screening // Different // Comparison // Helping Behavior // strategy // National citizen // Professional guide // Recommendation // Aspects of disease screening // 
Model // Six // Independence // Created By // Part of // Groups // Intervention regimes // National Cancer Institute // Consortium or Network // Surveillance Modeling // 
Creation // Model // shared attribute // Use of // Age // Set scale // Variable (uniformity) // Specific qualifier value // objective (goal) // In addition to // Screening - procedure intent // Efficient // Gain // strategy // Reduction - action // Mortality Vital Statistics // Life // Gain // Additional // year // Screening mammography // 
Aspects of disease screening // Seven // Use of // Aspects of disease screening // Eight // Present // strategy // Efficient // To // Mortality Vital Statistics // Reduced // Six // And // strategy // Eight // Beginning // Screening - procedure intent // Age-Years // 
Act Class - review // Conclude Resin // strategy // % live // More // Extent // Commit Operation // Woman // Aspects of disease screening // Arabic numeral 69 // Old // Extent // year // Woman // Aspects of disease screening // /40 // Age // year // 
Benefits // Life // Numbers // Gain // year // Aspects of disease screening // Aspects of disease screening // /40 // Age Started // Within // year // Eight // Four // strategy // 
annual screening // strategy // Efficient // Malignant neoplasm of breast // Reduced // Increasing // Mortality Vital Statistics // year // Life // Evaluation and management note:Finding:Point in time:{Setting}:Document:{Provider} // Gain // More // Journalist // Resources // 
Imaging Techniques // 
Accepted // Ultrasonography // Evaluation procedure // Imaging Techniques // 
CDISC SDTM Evaluator Terminology // utilization qualifier // Mammography finding // Inconclusive (qualifier value) // Patients // Young // Woman // Other // Breast tissue sample // Dense // Tissue Specimen Code // Guide device // Method of biopsy // Core needle biopsy // Well Differentiated // And // Cyst // Mass of body structure // Solid // 
Negation // Disease Screening // Recommendation // Preposition For // Diagnostic Radiology Modality // Average // Woman // Malignant neoplasm of breast // Risk // 
Options // Ultrasonography // Disease Screening // Additional // Woman // Present // Magnetic Resonance Imaging // High risk of // Disease Screening // 
Table - furniture // 
Relative Risk // Pooled Sample // Mortality Vital Statistics // Malignant neoplasm of breast // Screening mammography // From // Age // Clinical Trials // 
1+ Score, WHO // PREVENT (product) // 
death age // Malignant neoplasm of breast // 
Including (qualifier) // Clinical Trials // Mortality Vital Statistics // N not otherwise specified Antibody // Costa Rica // Costa Rica // 


Arabic numeral 68 // Arabic numeral 69 // 
Not available // 1+ Score, WHO // 
Costa Rica // Abbreviations // Data Type Interval // credibility // Needs // Numbers // Relative Risk // Trial Screening // year // 
health insurance plan // New York (geographic location) // Largest // National citizen // CANADIAN // Screening Study // Entire breast // Two // Swedish // Clinical Trials // County // Clinical Trials // 2+ Score // Age // Clinical Trials // Clinical Trials // 
CANADIAN // Entire breast // National citizen // Swedish // Screening Study // County // Two // 2+ Score // Clinical Trials // Clinical Trials // 
Clinical Trials // 
Two // Swedish // Clinical Trials // County // 
Two // Swedish // Clinical Trials // County // 
Authorization documentation // Reprint // KNG1 gene // K Prime // Trial Screening // 
Malignant neoplasm of breast // United States // Update // Advisory Committees // Preventive service healthcare // 
Intern // 
Negation // Magnetic Resonance Imaging // Receive // Contrast // Gadolinium // Claustrophobia // History of allergies // BARRIER // 
Magnetism // Mammography // diagnostic use // Duration (temporal concept) // Financial cost // Contrast Media // Injection of therapeutic agent // geographic population // Prohibit // 
Problem // American Cancer Society // Use of // Guideline [Publication Type] // Preposition For // Magnetic Resonance Imaging // High risk of // Disease Screening // Female Breast Carcinoma // Woman // Including (qualifier) // Risk // Woman // 

Known // BRCA2 Gene Mutation // 

BRCA2 Gene Mutation // Testing // Negation // Self // 

Lifetime Risk // Largest // Malignant neoplasm of breast // Scientific Equipment // Risk Assessment // Family History Domain // Base - General Qualifier // 

To // History of radiation therapy // Age-Years // Anterior thoracic region // year // 

Genetic syndrome // Lithium Cation // Including (qualifier) // Hamartoma Syndrome, Multiple // Syndrome // One // Ruvalcaba Syndrome // First Degree Relative // Adverse Event Associated with Syndromes // 
Conclude Resin // Laboratory Order Panels // Evidence of // Insufficient (qualifier) // Magnetic Resonance Imaging // Recommendation // Preposition For // Aspects of disease screening // Personal Attribute // Woman // Carcinoma in Situ // History of malignant neoplasm of breast // Mammographic breast density // Atypical hyperplasia // 
Negation // Multisection:Finding:Point in time:Breast:Narrative:MRI // Aspects of disease screening // Recommendation // At risk // Woman // Malignant neoplasm of breast // Average // 
Computers // Ultrasonography, Doppler, Color // Detection // Helping Behavior // Digital breast tomosynthesis // Positron-Emission Tomography // promise // Show // Clinical // Choose (action) // Mammography // To // Breast Carcinoma // 
Negation // Romania // consider // Mammography // Tines // 
Digital Mammography // 
Digital // Diagnostic Imaging // Mammography finding // Reporting // Screening Study // 
per year // 2+ Score // Period (temporal qualifier) // Study // Study // Woman // Site // From // Canada // United States // 
Digital Mammography // Participant // Randomization // Film Mammography // Order (arrangement) // 
Diagnostic Accuracy // film (photographic) // Digital Mammography // Entire // Similarity // geographic population // 
Digital Mammography // film (photographic) // Upper // Woman // Mammography // year // Young // Dense // Woman // Pauses:Number = Count/Time:Duration of the study:Heart:Quantitative:EKG // Dense breasts NOS // Woman // Perimenopausal // 
Reporting // research outcome // 
Screening - procedure intent // Clinical Trials, Randomized // Full field // film (photographic) // Population Programs // Digital Mammography // Disease Screening // Base - General Qualifier // Age // Woman // Mammography // Woman // Digital Mammography // N not otherwise specified Antibody // N not otherwise specified Antibody // 
Woman // Cancer Detection // Women's Groups // P Blood group antibodies // Mammography // Population Group // 
Recent // Data // Meta-Analysis (publications) // Large // Eight // Scientific Study // Randomization // Overall Publication Type // Present // Mammography // Digital // Value Above Reference Range // Slightly // Rating (action) // Detection // Woman // Film Mammography // year // Age // Young // 
Clinical // Recommendation // consideration // 
Breast Self-Examination // Menopause // Self awareness // Entire breast // Effectiveness // Screening procedure // 
Performance // Breast Self-Examination // Breast // Nation // Consistent with // Present // Persons // systematic // Basis - conceptual entity // Regular // Monthly (qualifier value) // 
Physicians // CTSE gene // ethylene diurea // Performed // Patients // Focal // prevention through information dissemination // Intervention regimes // 
Appropriate // High Risk Populations // Certain (qualifier value) // Woman // And // To // Choose (action) // Approach // Followed by // 
Biological Evolution // Current (present time) // concept // Educational process of instructing // Awareness // Self-Examination // 
American Cancer Society // College // Self awareness // Entire breast // Normal appearance (finding) // Nes (fish) // Breast // Emotions // 
Approximate // concept // Half // One // Old // Case unit dose // Case unit dose // Within // Detection // year // FRZB gene // Woman // 
Self Efficacy // Add - instruction imperative // Science of Statistics // Wiskott-Aldrich Syndrome // 
Self awareness // Entire breast // Breast Self-Examination // Include (action) // 
desires // Woman // Performed // To // Examination of breast // Self awareness // strategy // Part // Techniques // Appropriate // Examination by method // Negation // 
Reporting // Woman // Health Personnel // Breast changes // 
strategy // Respiratory Therapist, Registered - Patient Education // Study Start Date // Negation // Awareness // Entire breast // Part of // Exist // strategy // Screening procedure // Negative Finding // Woman // Clinical Breast Examination // Mammography // Exclusion // Experimental Result // Malignant neoplasm of breast // Pressure- physical agent // 
Case unit dose // New // Screening procedure // Primary malignant neoplasm // Entire breast // Interval // Prompt // Self awareness // Negation // Woman // Reporting // Deferred // Base - General Qualifier // Breast changes // Group reassurance // False Negative Result Medical Device Problem // Screening procedure // Recent // 
Self awareness // Entire breast // To // Aim (idea) // Detection // subscriber - self // Symptom Evaluation // Prompt // Overall Publication Type // Relate - vinyl resin // morbidity aspects // Malignant neoplasm of breast // Mortality Vital Statistics // 
Effect // Self awareness // Entire breast // Negation // Educational Status // Study // 
Recommendation // Breast Self-Examination // education evaluation // Arabic numeral 23 // 
CER tumor staging notation // Regular // Woman // Detection // Breast Self-Examination // subscriber - self // Arabic numeral 31 // Breast self-examination technique education // Receive // Follow-Up Report // In addition to // Screening for malignant neoplasm of breast // No Information Available // Delta (difference) // Reporting // Relationships // Malignant neoplasm of breast // Cessation of life // 

Review, Systematic // Including (qualifier) // Scientific Publication // Clinical Trials // Entire breast // Population Based Study // Large // Breast Self-Examination // Russia // Intervention regimes // 
Clinical Trials // Biopsy // Twice (Numerical Qualifier) // Experimental Result // Benign // Screening procedure // Performed // Control Groups // Population Group // 
Advisory Committees // CANADIAN // Recommendation // preventive health care // Breast Self-Examination // Educational process of instructing // Fair (qualifier) // Base - General Qualifier // Breast Self-Examination // Evidence of // Good // Benefits // Evidence of // 
Act Class - review // Evidence of // Additional // Practice Experience // Patients // Worried // Increase // Mental Depression // Anxiety // Breast Self-Examination // Associated with // 
Mammography // Screening procedure // False Negative // Clinical Breast Examination // Woman // Primary malignant neoplasm // Primary malignant neoplasm // Woman // 
Primary malignant neoplasm // College // Educational process of instructing // Consortium or Network // Elderly (population group) // Woman // Old // year // Self awareness // Entire breast // 
Screening for cancer // Clinical // 
Frequent // Somalia // Performed // 
Use of // National citizen // Data // early detection of cervical cancer // Entire breast // Clinical Breast Examination // Program // Community // Performed // Woman // {Setting} // /40 // Elderly (population group) // Old // year // Clinical Breast Examination // Conclude Resin // Cancer Detection // alone - group size // Specificity // In addition to // 
Five // Population Group // Primary malignant neoplasm // Case unit dose // Clinical Breast Examination // Detection // Formed // 
Physical findings // Abnormal Reference Range // Entire breast // Normal // Mammography // Primary malignant neoplasm // Case unit dose // Screening procedure // Detection // 
Conclude Resin // Journalist // Clinical // Add - instruction imperative // Better // Examination of breast // Early Diagnosis // 
Numerous // Supportive assistance // Review [Publication Type] // Clinical // Combined // Mammography // Examination of breast // Screening for malignant neoplasm of breast // 
Study // Statistical sensitivity // Better // Comparison // Breast Cancer Detection Research // In addition to // Mammography // Mammography // Clinical Breast Examination // alone - group size // 
False Discovery Rate // Population Group // Value Above Reference Range // Clinical Breast Examination // Receive // Single Group Study // Mammography // 
Availability of // Base - General Qualifier // College // Evidence of // National Comprehensive Cancer Network // American Cancer Society // Examination of breast // Recommendation // Annual // Performed // Elderly (population group) // Woman // year // /40 // Old // 
Numerical value // Clinical // Aspects of disease screening // Preposition For // Examination of breast // Low Prevalence // Woman // Woman // Malignant neoplasm of breast // year // Elderly (population group) // Clear // Negation // American Cancer Society // College // Continuous // National Comprehensive Cancer Network // Recommendation // To // Female breast // Clinical // 1+ Score // Nation // year // 
Mammography // Frequent // Beginning // Performed // Mammography // 
incidence of cases // Base - General Qualifier // Sojourn // Malignant neoplasm of breast // Malignant neoplasm of breast // Time // Potential // growth aspects // Cancer Death Rate // Reduction mammaplasty // Recommendation // College // Age // Woman // year // /40 // Offered // Old // Mammography // Disease Screening // Annual // 
Screening Tests // Educational process of instructing // Woman // False Negative Result Medical Device Problem // Predictive Value // 
Informed // Woman // Additional // Potential // Biopsy // Imaging Techniques // Base - General Qualifier // Recommendation // Growth Inhibition Screening Result // 
Physicians // Patients // Work // Disease Screening // best (quality) // Valine // Risk // Woman // Undifferentiated (Embryonal) Sarcoma // More // Disease Screening // Acceptable // Appropriate // strategy // 
Average // Woman // Risk // Maintenance // Disease Screening // Disease Screening // Most // Woman // Testing // annual screening // 
Various patch test substance // Offered // Population Group // Timing // Recommendation // Frequencies (time pattern) // Initiation // Aspects of disease screening // 
Population Group // Change values // Place // Scientific Publication // consideration // Cost Effectiveness // Evidence of // Accurate (qualifier) // Efficiency // Statistical sensitivity // Specificity // False Negative Result Medical Device Problem // False Positive // Compliance behavior // Positive Predictive Value of Diagnostic Test // health care resources // Availability of // Needs // Health Care // Advocate (person) // Expert Opinion // 
Recommendation // Summary (document) // Table - furniture // Present // 
National Comprehensive Cancer Network // American Cancer Society // annual screening // Recommendation // Beginning // Mammography // /40 // Age-Years // 
United States // Contrast // Advisory Committees // Preventive service healthcare // Changing // Recent // MEND ashed powder // Guideline [Publication Type] // Woman // Mammography // year // Elderly (population group) // 
Woman // Routine // Negation // year // Advisory Committees // Recommendation // Woman // Aspects of disease screening // year // Young // Patient Base // Individualized // Specific qualifier value // Values // Arabic numeral 23 // Benefits // 
National Comprehensive Cancer Network // American Cancer Society // Preventive service healthcare // United States // Agree // Advisory Committees // Relationships // Screening mammography // Elderly (population group) // Female Breast Carcinoma // year // /40 // Base - General Qualifier // Old // Availability of // Meta Analysis (statistical procedure) // Screening mammography // Randomized Controlled Trials as Topic // Table - furniture // Vision // 
Preventive service healthcare // United States // Arrival - action // Advisory Committees // Conclusion // Different // Aspects of disease screening // Routine // Place // Woman // Weight // Greater // Lower - spatial qualifier // Upon - dosing instruction fragment // Population Group // disorder prevalence // Mammography // Positive Predictive Value of Diagnostic Test // Numbers // Increase // To // Needs // To // Screening - procedure intent // One // PREVENT (product) // Relationships // Malignant neoplasm of breast // Cessation of life // 
Add - instruction imperative // Preventive service healthcare // United States // Woman // Advisory Committees // Screening for malignant neoplasm of breast // Within // False Positive // Practice Experience // High // Mammography // Status post // Woman // Aspects of disease screening // year // Diagnostic Imaging // Additional // psychological distress // Biopsy // 
Additional // Burden // Perception // Laboratory Procedures // Woman // Greater // /40 // Elderly (population group) // Less Than // year // Practice Experience // Probably // Less Than // Malignant neoplasm of breast // Benefits // Probably // Arabic numeral 23 // Aspects of disease screening // 
Disease Response // Within // HERPUD1 gene // Programming Parameter // Routine // Data Port // Woman // Aspects of disease screening // Note:Finding:Point in time:{Setting}:Document:Nursing // /40 // Primary malignant neoplasm // incidence of cases // /40 // Less Than // Human Age Group // per year // Old // Woman // incidence of cases // year // Within // Primary malignant neoplasm // 1+ Score // Woman // Negation // Integer +2 // Within // High // /40 // Woman // Arabic numeral 69 // 1+ Score // Integer +2 // 1+ Score // 
Woman // Add - instruction imperative // Screening mammography // Routine // parable // /40 // Reduction - action // Mortality Vital Statistics // Woman // Comparison // Screening mammography // Routine // Reduction - action // Reduction - action // 
per year // Each (qualifier value) // Malignant neoplasm of breast // United States // Woman // Diagnosis // year // Young // 
Aspects of disease screening // Frequencies (time pattern) // Preventive service healthcare // United States // Recommendation // Advisory Committees // Base - General Qualifier // Decision // Aspects of disease screening // National Cancer Institute // Prediction // Model // Aspects of disease screening // Within // Reduction - action // Mortality Vital Statistics // Aspects of disease screening // Main // 
strategy // This // Experimental Result // Positive Finding // Arabic numeral 23 // 
Model Number // Annual // Aspects of disease screening // strategy // Anterior // Aspects of disease screening // Within // 
Consequence of // Potential // Screening mammography // 
Potential // Malignant neoplasm of breast // Result // Mammography // Screening - procedure intent // False Positive // include - SetOperator // False Negative // gram // overdiagnosis // Mammography // 
Risk // Concern // Egypt // Exposure to radiation // Exposure to radiation // Malignant neoplasm of breast // Improvement // Decreased // Technology // Techniques // Experience // Clinical // 
Mammography // False Positive // Further // Congenital Abnormality // Verification // Evaluation // Negation // Lesion // Continuous // Primary malignant neoplasm // Concern // 
False Positive // Diagnostic Mammography // Screening mammography // Ultrasonography // View // Case unit dose // biopsy characteristics // Reaching // Attempt // Diagnostic Accuracy // 
Treatment/Psychosocial Effects // Aspects of disease screening // Consequence of // Distress // Anxiety // Reviewed // Identified // % live // Short // Severe (severity modifier) // Negation // 
Evaluation // Scientific Study // False Positive // Effect // Woman // suggestion // High // United States // False Positive // Tolerant // Woman // Mammography // False Positive // Experience // More // Mammography // Woman // Probably // Immobile // Normal result // Aspects of disease screening // Routine // Future // 
Woman // More // False Positive // Anxiety // Probably // Pathologic // Malignant neoplasm of breast // Disease classification level // 
Factor // Woman // Increase // Malignant neoplasm of breast // Relative Risk // 
Female Breast Carcinoma // Most // Nose // Invasive // Unique // Negation // Act Code - risk factors // Identified // Certain (qualifier value) // Woman // Increase // Characteristics // Malignant neoplasm of breast // Prevalence aspects // General Population // Comparison // 
Malignant neoplasm of breast // Incidence // Advance // Increase // Integer +2 // Age // 
High risk of // Woman // To // Patient need for (contextual qualifier) // Increase // Counsel - legal // Reduction mammaplasty // Medical Surveillance // Physicians // Cancer Risk // Assessed // Periodic // Risk // Malignant neoplasm of breast // 
Risk Assessment // Act Mood - Goal // Risk // Woman // Average // Levels (qualifier value) // High // Age // High risk of // 
Risk Assessment // Used by // Negation // consider // To // Disease Screening // Woman // Age // Appropriate // Disease Screening // Enhance (action) // Magnetic Resonance Imaging // Add - instruction imperative // More // Screening procedure // Clinical Breast Examination // Frequent // strategy // Risk Reduction // 
Risk // Reproductive History // 
Entire breast // Certain (qualifier value) // Risk // CER tumor staging notation // Age at menarche // Including (qualifier) // First Birth // Age // Parity:Number:Point in time:^Patient:Quantitative:Reported // Breast Feeding // Table - furniture // Age at menopause:Time:Point in time:^Patient:Quantitative // 
REPRODUCTIVE // Numbers // Age // year // Lower - spatial qualifier // First Birth // Nulliparity // Parity:Number:Point in time:^Patient:Quantitative:Reported // Malignant neoplasm of breast // Increase // Risk // 
Familial risk factor // 
Entire breast // consideration // Family history // Assessment for risk of cancer // Malignant neoplasm of breast // Case unit dose // Malignant neoplasm of prostate // Malignant neoplasm of ovary // Type - attribute // Other relative // parent // Degree or extent // Child // Sibling - RoleCode // Age // Second Suffix // Malignant Neoplasms // member // 
Woman // Base - General Qualifier // consideration // Evaluation // 
Table - furniture // 
Factor // Relative Risk // Increase // Woman // Malignant neoplasm of breast // 
Factor // Relative Risk // 
Woman // 
Age // Risk // Arabic numeral 65 // Age // Increase // Breast Cancer, Familial // Definitely Related to Intervention // Mutation // 
BRCA2 gene // 
More // Two // Malignant neoplasm of breast // Number of First Degree Relatives (Affected) // Early // Diagnosis // Social and personal history // Age // Cancer confirmed // Atypical hyperplasia of breast // Body tissue // Abnormally high // Biopsy // density // 
First Degree Relative // One // Malignant neoplasm of breast // With - dosing instruction fragment // Bone Density // High-LET Radiotherapy // Postmenopausal state // 
Factor // Affect (mental function) // 
Early menarche // year // 
Circulating // Late // Hormones // Arabic numeral 55 // Menopause // Full Term finding // year // Never (frequency) // Pregnancy // Recent // Offspring // Recent // ORAL CONTRACEPTIVE INGESTION // Use of // Long-term // Estrogens // 
Progestins // Postmenopausal state // Obesity // 
Factor // Other Personal Medical History // Endometrial // Personal Attribute // Alcohol consumption // Malignant neoplasm of ovary // Precursor T-Cell Lymphoblastic Leukemia-Lymphoma // Height // Socioeconomic Status // Abnormally high // Heritage // Ashkenazi Jew, follower of religion // 
Authorization documentation // Reprint // American Cancer Society // 
Malignant neoplasm of breast // 2010s // 
Atlanta // American Cancer Society // 
Adapt (substance) // Moorman // Authorization documentation // Prostaglandin measurement // 
Malignant neoplasm of breast // risk factors // Hormones // 

Discussion (procedure) // 1+ Score, WHO // 

Breast // Hereditary // Syndrome // Malignant neoplasm of ovary // 
Factor // Combined // 
Risk Assessment // Gail Risk Model // utilization qualifier // Scientific Equipment // Age // Patients // Limited (extensiveness) // Reproductive History // Malignant neoplasm of breast // Family history // Woman // Number of First Degree Relatives (Affected) // Biopsy of breast // History of previous events // &gt;5 // Estimated // Lifetime Risk // per year // Malignant neoplasm of breast // 
Model // Woman // Caucasoid Race // African American // Study // Woman // 
Assessed // /minute // Complete // Internet // Availability of // RAB3D gene // Primary malignant neoplasm // 
Estimated // Woman // A 7 // To // Malignant neoplasm of breast // per year // Greater // Risk // Average // Equal // Offered // Greater // Aspects of disease screening // Enhance (action) // Clinical Breast Examination // Including (qualifier) // per year // month // Educational process of instructing // Mammography // subscriber - self // Entire breast // 
Negation // Gail Risk Model // Risk Assessment // Good // Strong // Scientific Equipment // Present // Family history of breast cancer // Mother (person) // Woman // Patients // Sister // Malignant neoplasm of breast // Family history of cancer // Malignant neoplasm of ovary // Egypt // 
Negation // Multisection:Finding:Point in time:Breast:Narrative:MRI // Base - General Qualifier // MEND ashed powder // Gail Risk Model // 
Disease Screening // Woman // Appropriate // High risk of // 
BRCA2 gene // Disease Screening // Enhance (action) // Annual // Recommendation // Annual // Nation // Annual // Mammography // Self-Examination // Multisection:Finding:Point in time:Breast:Narrative:MRI // 
Management procedure // Details // Mutation // Woman // 
Entire breast // Hereditary // Syndrome // Ovarian Carcinoma // 
Degree or extent // Woman // Management procedure // Relative (related person) // Carrying // aldosterone secretion inhibitory factor // Mutation // 
Woman // To // Estimated // Malignant neoplasm of breast // Lifetime Risk // Base - General Qualifier // Largest // Model // Risk // BRCAPRO // Family history // Negative // Testing // Mutation // brca gene // Enhance (action) // Offered // described // Disease Screening // Mutation Carrier // 
Risk Reduction // consider // strategy // Woman // 
Woman // High risk of // consider // Case unit dose // Future // Receive // Malignant neoplasm of breast // Therapeutic procedure // Therapeutic radiology procedure // Age-Years // Lymphoma // year // 
Woman // Receive // To // Mammography // Annual // Magnetic Resonance Imaging // Annual // Clinical Breast Examination // Disease Screening // month // Distance vision 6/12 // year // Beginning // Therapeutic procedure // Receive // Occurrence // Age-Years // Last // 
Social and personal history // Female breast // High risk of // Carcinoma in Situ // Including (qualifier) // Increase // are unit of measure // Future // Risk // Malignant neoplasm of breast // 
Woman // Enhance (action) // Receive // Including (qualifier) // Screening procedure // Mammography // Annual // Distance vision 6/12 // Clinical Breast Examination // Educational process of instructing // month // Organization administrative structures // Woman // 
Personal Attribute // Woman // Ductal // H/O: carcinoma // Invasive Breast Carcinoma // In situ // Anti-Mullerian Hormone Receptor Type II // Preventive monitoring // 
Age // Upper // Risk // Range // Mammography // 
Recommendation // Negation // Problem // Exist // 
Medical // Life Expectancy // Comorbidity // Screening for malignant neoplasm of breast // consider // Woman // Program // year // Old age // Benefits // Old // Decrease // Screening mammography // Advance // Comparison // Age // 
Woman // year // Old age // Within // Old // Physicians // Consultation // Continuous // Negation // Disease Screening // 
Increasing // Invasive // Mortality Vital Statistics // Racial group // Malignant neoplasm of breast // &lt;3 (qualifier value) // Age-Years // 
Mammography // Most // Upper // Trial Screening // Limited (extensiveness) // Age // Range // criteria // year // year // 
Conclude Resin // Meta-Analysis (publications) // Woman // Screening mammography // year // Old age // Cost Effectiveness // Moderation // Increase // Small // Life Expectancy // 
Summary (document) // Conclusion // Recommendation // 
Recommendation // Following // PDLIM5 gene // Base - General Qualifier // Science // Inconsistent // Levels (qualifier value) // Evidence of // 
incidence of cases // Base - General Qualifier // Sojourn // Malignant neoplasm of breast // Malignant neoplasm of breast // Time // Potential // growth aspects // Malignant neoplasm of breast // Reduction - action // College // Mortality Vital Statistics // Woman // Recommendation // /40 // Old age // Old // year // Aspects of disease screening // Offered // Annual // Mammography // 
Expert Opinion // Consensus // 
Performed // Clinical Breast Examination // Woman // Annual // /40 // Old age // Old // year // 
Old age // Woman // Clinical Breast Examination // year // 1+ Score // Recommendation // year // 
Entire breast // Include (action) // Self awareness // Breast Self-Examination // 
Woman // Breast changes // Report (document) // Health Personnel // 
Woman // Predictive Value // Educational process of instructing // Potential // Screening mammography // False Negative Result Medical Device Problem // False Positive // 
Informed // Woman // Potential // 






Age // 1+ Score // Fig Flavor // 
incidence of cases // Female Breast Carcinoma // Age // Death Rate // United States // Racial group // 
incidence of cases // Data // North American Association of Central Cancer Registries // 
Mortality Vital Statistics // Centers for Disease Control and Prevention (U.S.) // National Center for Health Statistics (U.S.) // 
Authorization documentation // Reprint // American Cancer Society // 
Malignant neoplasm of breast // 2010s // 
Atlanta // 
Rate // 
American Cancer Society // 
Imaging Techniques // Additional // MEND ashed powder // Biopsy // Growth Inhibition Screening Result // Base - General Qualifier // 
Estimated // Woman // Lifetime Risk // To // Largest // Malignant neoplasm of breast // Risk // Base - General Qualifier // Family History Domain // Diabetes Mellitus, Non-Insulin-Dependent // Testing // BRCAPRO // brca gene // Negative // Offered // Mutation // Disease Screening // Enhance (action) // 
Negation // Multisection:Finding:Point in time:Breast:Narrative:MRI // Disease Screening // Recommendation // At risk // Woman // Malignant neoplasm of breast // Average // 
BRCA2 Gene Mutation // Woman // Disease Screening // Enhance (action) // Risk Reduction // MEND ashed powder // 
Reference Object // 
1+ Score, WHO // 
Act Code - Ward // R prime // MJ // hydroxylamine oxidase activity // 
Science of Statistics // Primary malignant neoplasm // 
CLIN // 

Level 3 // 
Integer +2 // 
Chloride Ion // R prime // M+ (tumor staging) // Editor // 
Surveillance, Epidemiology, and End Results (SEER) Program // Stat (do immediately) // Primary malignant neoplasm // Act Class - review // 
Institutes // 
HTTP // Availability of // Primary malignant neoplasm // Surveillance, Epidemiology, and End Results (SEER) Program // RAB3D gene // 

Level 3 // 
&lt;3 (qualifier value) // 
American Cancer Society // 
2010s // Malignant neoplasm of breast // 
Atlanta // 
Availability of // Internet // HTTP // Professional Organization or Group // Primary malignant neoplasm // Contents // Groups // Act Relationship Type - documents // 

Level 3 // 

Decrease // Ej // incidence of cases // Malignant neoplasm of breast // United States // 
N not otherwise specified Antibody // EXOG gene // 
Level III // 
Integer +5 // 
Glass (substance) // Doctor of Law // Junior // U2AF1 wt Allele // 
Malignant neoplasm of breast // 1980s // incidence of cases // Social Role // Psychotherapy, Multiple // Hormones // Pauses:Number = Count/Time:Duration of the study:Heart:Quantitative:EKG // Mammography // Aspects of disease screening // Encounter due to estrogen receptor status // 
Primary malignant neoplasm // 
Level 3 // 


Continuance of life // Negative Lymph Node // Factor // research outcome // Malignant neoplasm of breast // Longterm Follow-up // 
Primary malignant neoplasm // 
Level III // 

Test Method // Result // Long-term // Tumor stage T1a // Woman // Invasive Breast Carcinoma // Tumor stage T1b // Published Erratum // Prospective Studies // Lancet // Appearance // 2000s // 
Lancet // 2000s // 
Level 3 // 

Diagnosis Study // New // Malignant neoplasm of breast // 
Surg // Laboratory Vendor Name // CLIN // 2000s // 
Level III // 

Late // Protons // Breast Carcinoma // 
Primary malignant neoplasm // 
Level 3 // 

MJ // Creatinine measurement // 
twenty twenty // follow-up // per year // CD8A wt Allele // Mini // Breast Cancer Detection Research // Malignant neoplasm of breast // Project // 
Surg // CLIN // 
Level 3 // 

Surviving free of recurrence of neoplastic disease // Gram per Deciliter // Small breast // Patients // Primary malignant neoplasm // 
PDGFB wt Allele // Less Than // Primary malignant neoplasm // And // Detection // Aspects of disease screening // 



Iodides // H/O: carcinoma // Natural // Breast // 

Level III // 


History of malignant neoplasm of breast // Natural // 
Hyperplasia // Disease Progression // Prediction // Neoplasm // Electrospray Ionization // angiogen // 
Primary malignant neoplasm // 
Level III // 

Protons // 
Increasing // Breast Cancer Detection Research // Exertion // 
F11R gene // 
Level III // 

ELANE wt Allele // day // 
Preclinical // Statistical Estimation // Geographic state // illness length // Disease Screening // Use of // Data // 

Level III // 


Malignant neoplasm of breast // Clinical Trials, Randomized // Learning // Aspects of disease screening // 
North // CLIN // 
Level III // 

Potassium Ion // Screening for malignant neoplasm of breast // KNG1 gene // United States // Update // Advisory Committees // Preventive service healthcare // 
Preventive service healthcare // United States // Advisory Committees // 
Intern // 
Level III // 

M NOS ANTIBODY // Saint Helena Islands // KNG1 gene // 
Summary (document) // Screening for malignant neoplasm of breast // Evidence of // 
United States // Advisory Committees // Preventive service healthcare // 
Intern // 
Level III // 

Fuchsin acid stain // K Prime // MEGALENCEPHALIC LEUKOENCEPHALOPATHY WITH SUBCORTICAL CYSTS // San Marino // 
Screening mammography // Efficacy Study // PDGFB wt Allele // 
F11R gene // 
Meta Analysis (statistical procedure) // 

Respiratory Domain // Axial R // Smith (occupation) // Third // HFE2 gene // Creatinine measurement // 
New // Randomization // Meta Analysis (statistical procedure) // 
Meta Analysis (statistical procedure) // 

PROC wt Allele // 
Aspects of disease screening // Act Class - review // Malignant neoplasm of breast // Preposition For // Publishing // Mammography // Tums // ESRRA gene // Lancet // Appearance // 
Lancet // 
Level III // 

HPS4 gene // Iodides // 
Mammography // Longterm Effects // Update // Trial Screening // Swedish // overview // Published Erratum // Clinical Trials // Lancet // Appearance // 
Lancet // 
Level III // 
Arabic numeral 23 // 
Screening for malignant neoplasm of breast // Preventive service healthcare // United States // Recommendation // Advisory Committees // Statement // 
Preventive service healthcare // Published Erratum // Advisory Committees // Intern // Appearance // Intern // 2010s // 2010s // 
Intern // 
Level III // 

Vorinostat // Aspects of disease screening // Cost Effectiveness // Age-Years // Mammography // Review, Systematic // Arabic numeral 65 // Preventive service healthcare // United States // Advisory Committees // 
Financial cost // Groups // Work // Preventive service healthcare // United States // Advisory Committees // 
Intern // 
Level III // 

Morphology Findings Domain // Guideline [Publication Type] // American Cancer Society // Aspects of disease screening // 
American Cancer Society // Groups // Malignant neoplasm of breast // Appearance // Published Erratum // CLIN // Malignant Neoplasms // 


M NOS ANTIBODY // Endocrine System Findings Domain // Diagnostic // SLC14A1 gene // Digital // performance - action // 
Screening for malignant neoplasm of breast // Film Mammography // 
Mammography // digital imaging // Research Personnel // Screening Study // Published Erratum // User Group // EXOG gene // Appearance // 1840s // 
N+ (tumor staging) // EXOG gene // 
Level 3 // 

Screening - procedure intent // Clinical Trials, Randomized // Full field // film (photographic) // Soft // Digital Mammography // Reading (activity) // Copy (object) // Base - General Qualifier // Population Programs // follow-up // Disease Screening // research outcome // Diagnosis Type - Final // 
Radiology studies // 


C19orf26 gene // Immune System Findings Domain // Silvan // 
Digital // Full field // Film Mammography // Screening - procedure intent // Entire breast // Comparison // Program // Disease Screening // Taverns // Review, Systematic // Data // 
Radiology studies // 
Level III // 

Djibouti // Kenya // Gammon // Predictor // Patterns // Method of detection // Malignant neoplasm of breast // Age // Woman // Cancer Control // United States // Integer +5 // Etiology // 
Level 2 // 

newcomer // Entire breast // Method of detection // Histology // Automobiles // 
&lt;3 (qualifier value) // Primary malignant neoplasm // 
Level 3 // 
Arabic numeral 31 // 
Breast Self-Examination // M+ (tumor staging) // Malignant neoplasm of breast // Continuance of life // Follow-Up Studies // Longitudinal Studies // 
Observation Result // Malignant neoplasm of breast // Treatment intent // 
Level 2 // 

Radiation // Per Deciliter // EAR WAX, WET/DRY // Rostromedial auditory cortex // Clinical Trials, Randomized // Chen // Self // Entire breast // Experimental Result // Diagnosis Type - Final // 
Primary malignant neoplasm // 


PROC wt Allele // 
Self-Examination // Regular // Examination of breast // Clinical // CER tumor staging notation // Early Diagnosis // 
Review, Systematic // Databases // Problem // 
Arts // 


Digital Object Identifier // 

Meta Analysis (statistical procedure) // 

Update // preventive health care // Malignant neoplasm of breast // 
CANADIAN // preventive health care // Advisory Committees // 


North Carolina // SLC14A1 gene // 
Clinical Breast Examination // Procedure findings:Finding:Point in time:^Patient:Narrative // National citizen // Reporting // Program // Screening procedure // Primary malignant neoplasm // From // 2000s // 
Level 3 // 

Aspects of disease screening // M NOS ANTIBODY // Sojourn // Statistical sensitivity // Screening for malignant neoplasm of breast // Time // Mammography // Clinical Trial [Publication Type] // Physical Examination // 
CLIN // 
Level III // 

Iodides // Screening for malignant neoplasm of breast // 
Surg // 
Level III // 

M+ (tumor staging) // Screening for malignant neoplasm of breast // Screening mammography // 

Level III // 

fletchers' // African race // BLOOD GROUP--SWANN SYSTEM // KNG1 gene // Right // International // Report (document) // On (qualifier value) // Educational workshop // Screening for malignant neoplasm of breast // 
Primary malignant neoplasm // 
Level III // 
/40 // 
T prime // Miller // CANADIAN // Walls of a building // Entire breast // National citizen // per year // Screening Study // Randomization // Experimental Result // 
Woman // Clinical Trials // year // Elderly (population group) // 2000s // Primary malignant neoplasm // 


Contribution // Mycobacterium avium Complex // Examination of breast // Clinical // Screening for malignant neoplasm of breast // 
Level 2 // 

Older Population // Aspects of disease screening // American Cancer Society // Women, Working // Work // Mammography // American Cancer Society // User Group // Work // Physical Examination // American // User Group // Arabic numeral 69 // American // 


National Comprehensive Cancer Network // 
National Comprehensive Cancer Network // Entire breast // Clinical Practice Guideline // CER tumor staging notation // 
Washington state // National Comprehensive Cancer Network // Pairing Events Domain // 
Level III // 

POLK gene // BLOOD GROUP--SWANN SYSTEM // fletchers' // 
per year // Toxic Epidermal Necrolysis // False Positive // Risk // Clinical Breast Examination // Screening mammography // 
Level 3 // 

Potassium Ion // City of Berlin // 
Screening mammography // /40 // Woman // Age-Years // To // American College of Physicians // Review, Systematic // 
Intern // 
Level III // 

Variant // Right // Screening for malignant neoplasm of breast // Benefits // Age // 
Primary malignant neoplasm // 
Level III // 

KNG1 gene // 
Mammography // Psychosocial // 
Primary malignant neoplasm // 
Level III // 

KNG1 gene // 
Psychiatric problem // Mammography abnormal // Behavior // 
Intern // 
Level III // 


Screening mammography // Psychological Impact // 
Review, Systematic // 

Level III // 

Nuchal Translucency Screen // Brewer // 
Longterm Effects // Review, Systematic // Mammography // False Positive // 

Intern // 
Meta Analysis (statistical procedure) // 


Attitude // Woman // Mammography // False Positive // Noninfiltrating Intraductal Carcinoma // Detection // Cross-Sectional Studies // 
2000s // /40 // 
Level III // 

Screening for malignant neoplasm of breast // 
CLIN // Roman numeral VII // North // 
Level III // 

United States Agency for Healthcare Research and Quality // 
Evidence of // Diagnosis Study // Technology // Evaluation Report // 
United States Agency for Healthcare Research and Quality // 



Potassium Ion // Screening mammography // Continuous // IMPACT gene // Woman // Cost Effectiveness // Expectation // 

Databases // MEDLINE // American College of Obstetricians and Gynecologists // Libraries // Resources // Internal - CodeSystemType // Used by // Documents // Publications // Entire duct // To // Search - action // Article // Relevance // 1990s // Scientific Publication // 
Restricted // Search - action // Scientific Publication // Article // English Language // 
Priority // Article // Entity Name Part Type - given // Original // Reporting // Review [Publication Type] // research outcome // Published Comment // Article // Abstract Summary // Consultation // Science // Sia // Negation // Conferences // Sufficient // consider // Documents // Inclusion // 
Scientific Publication // Guideline [Publication Type] // Health // Organization administrative structures // Review [Publication Type] // American College of Obstetricians and Gynecologists // Scientific Study // Additional // Bibliography // Review [Publication Type] // Article // Identified // 
Research Activities // Reliability (characteristic) // Expert Opinion // Not available // Used by // Obstetrician and gynecologist // 
Review [Publication Type] // Scientific Study // Quality // Evaluation // United States // Methods // Advisory Committees // Preventive service healthcare // 
Evidence of // Iodides // Smaller // Obtain // One // 
Evidence of // Good // Obtain // CDISC Trial Design Class // Control function // 
Obtain // Evidence of // Design // Good // Clinical Study Case // Cohort // Scientific Study // control aspects // Central // One // 
Type - attribute // research study // Evidence of // 
III (suffix) // Base - General Qualifier // Authority // Description // Practice Experience // Report (document) // Scientific Study // Committee // 
Base - General Qualifier // Levels of Evidence // Highest // Recommendation // Data found // Grade // Providing (action) // Followed by // Agreement // Categories // 
Levels (qualifier value) // Base - General Qualifier // Recommendation // Good // 
Science // Evidence of // 
Levels (qualifier value) // Base - General Qualifier // Recommendation // Science // Limited (extensiveness) // Evidence of // 
Levels (qualifier value) // Base - General Qualifier // Recommendation // Expert Opinion // 
Html Link Type - copyright // College // American // Reservation (action) // Rights // Storage // Publications // System // Retrieval // Internet // Post // Manufactured form // Transmitted by // Authorization Mode - Electronic // Means // Photocopying // Mechanical Methods // Records // 
Request for // Make - Instruction Imperative // Authorization documentation // Direct type of relationship // Photocopying // Clearance [PK] // Html Link Type - copyright // Intrinsic drive // Central // 
Street address // American College of Obstetricians and Gynecologists // Oral // BLOOD GROUP--SWANN SYSTEM // Washington state // Box // 
Screening for malignant neoplasm of breast // 
Practice Experience // 

American College of Obstetricians and Gynecologists // 

